Moxetumomab Pasudotox

Category: Cancer

Moxetumomab Pasudotox Overview

Moxetumomab pasudotox is an anti-CD22 immunotoxin designed for the treatment of cancer.[1] Moxetumomab pasudotox is currently being developed by the biologics division of AstraZeneca, MedImmune. On 16 May 2013, the first dose in a Phase III trial was administered.[2][3] In Sept 2018 the US FDA approved it (as Lumoxiti) for some cases of relapsed or refractory hairy cell leukemia (HCL).[4] Discovery and ownership background On ...

Read more Moxetumomab Pasudotox Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Moxetumomab Pasudotox Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Moxetumomab Pasudotox
  • Injection: 1mg/vial
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Moxetumomab Pasudotox or a similar ingredient: (1 result)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 1 April 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA